Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
COEPW | US
0.00
13.04%
Healthcare
Biotechnology
30/06/2024
24/04/2026
0.01
0.01
0.03
0.01
Coeptis Therapeutics Holdings Inc. a biopharmaceutical company develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK a cell therapy for the treatment of CD38-related cancers including multiple myeloma chronic lymphocytic leukemia and acute myeloid leukemia; SNAP-CAR a CAR T cell therapy platform co-administered with tagged tumor-specific antibodies to potentially target different tumor types including hematological malignancies and solid tumors; and CD38-Diagnostic an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings Inc. is headquartered in Wexford Pennsylvania.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Asset (< 0.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
135.3%1 month
149.6%3 months
242.6%6 months
224.8%-
-
-
0.25
0.15
-
-
-
-23.93M
-
-
-
-
-
-
-1.45K
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.02
Range1M
0.02
Range3M
0.02
Rel. volume
16.16
Price X volume
47.48K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CURE Pharmaceutical Holding Corp | CURR | Drug Manufacturers-Specialty & Generic | 3.22 | 0 | 0.94% | n/a | |
| Biofrontera Inc. Warrants | BFRIW | Drug Manufacturers-Specialty & Generic | 0.0301 | 0 | n/a | 13.20% | |
| XOMAP | XOMAP | Biotechnology | 26.125 | 0 | 26.27 | 121.93% | |
| XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | XOMAO | Biotechnology | 25.4278 | 0 | -0.44% | 25.57 | 121.93% |
| Vaxxinity Inc. Class A Common Stock | VAXX | Biotechnology | 0 | 0 | -100.00% | n/a | 113.12% |
| SABSW | SABSW | Biotechnology | 0.0185 | 0 | 0.17 | 11.58% | |
| Revolution Medicines Inc. Warrant | RVMDW | Biotechnology | 4.43 | 0 | 3.02% | n/a | 5.40% |
| REVBW | REVBW | Biotechnology | 0.0092 | 0 | n/a | 0.00% | |
| Nutriband Inc. Warrant | NTRBW | Biotechnology | 1.17 | 0 | -2.50% | n/a | 1.72% |
| JSPRW | JSPRW | Biotechnology | 0.0155 | 0 | n/a | 2.31% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
No data | |||||||
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | - | 0.53 | - |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | - | 15.55 | - |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 242.65 | 72.80 | Riskier |
| Debt to Equity | 0.25 | -1.23 | Expensive |
| Debt to Assets | 0.15 | 0.25 | Cheaper |
| Market Cap | - | 3.66B | - |